Errata
4 March 2022
Associations of sarcopenia with graft failure and mortality in patients undergoing living donor liver transplantation
Ji‐Hoon Sim, Hye‐Mee Kwon, Kyung‐Won Kim, You‐Sun Ko, In‐Gu Jun, Sung‐Hoon Kim, Kyoung‐Sun Kim, Young‐Jin Moon, Jun‐Gol Song, Gyu‐Sam Hwang – 3 March 2022 – Recent studies have reported that sarcopenia influences morbidity and mortality in surgical patients. However, few studies have investigated the associations of sarcopenia with short‐term and long‐term graft failure in recipients after living donor liver transplantation (LDLT). In this study, we investigated the associations between sarcopenia and graft failure/mortality in patients undergoing LDLT.
Reply
Paul H. Hayashi, M. Isabel Lucena – 3 March 2022
Single‐cell profiling of human CD127+ innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma
Yuanlin He, Jiajing Luo, Guannan Zhang, Yu Jin, Nanxi Wang, Jinying Lu, Changxian Li, Xiaohuan Guo, Na Qin, Juncheng Dai, Yun Chen – 3 March 2022
mRNA and gene editing: Late breaking therapies in liver diseases
Nerea Zabaleta, Laura Torella, Nicholas D. Weber, Gloria Gonzalez‐Aseguinolaza – 3 March 2022 – The efficient delivery of RNA molecules to restore the expression of a missing or inadequately functioning protein in a target cell and the intentional specific modification of the host genome using engineered nucleases represent therapeutic concepts that are revolutionizing modern medicine.
Acute cellular rejection in liver transplantation recipients following vaccination against coronavirus disease 2019: A case series
Raiya Sarwar, Oyedele A. Adeyi, John Lake, Nicholas Lim – 3 March 2022
Ten‐eleven translocation‐2 inactivation restrains IL‐10‐producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma
Zhou Lu, Ronghua Liu, Yining Wang, Mengxia Jiao, Zhongchen Li, Zhiqiang Wang, Cheng Huang, Guoming Shi, Aiwu Ke, Luman Wang, Ying Fu, Jie Xia, Haoyu Wen, Jian Zhou, Xiaoying Wang, Dan Ye, Jia Fan, Yiwei Chu, Jiabin Cai – 3 March 2022
Improving the repopulation capacity of elderly human hepatocytes by decoding aging‐associated hepatocyte plasticity
Yun‐Zhong Nie, Yun‐Wen Zheng, Hideki Taniguchi – 3 March 2022
Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation
Gaby Danan, Rolf Teschke – 3 March 2022
Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
Wei Hou, Bryan Bridgeman, Greg Malnassy, Xianzhong Ding, Scott J. Cotler, Asha Dhanarajan, Wei Qiu – 2 March 2022 – Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown. In this study, we established two lenvatinib‐resistant (LR) HCC cell lines and identified integrin subunit beta 8 (ITGB8) as a critical contributor to lenvatinib resistance in HCC.